natgillin/translations-raw huggingface dataset:
• heart problems or blood clots in the lungs (difficulty breathing, chest pain) or other organs
• težave s srcem ali krvni strdki v pljučih (oteženo dihanje, bolečina v prsih) ali drugih organih,
These cases were associated with adverse reactions consistent with the known safety profile of lenvatinib (i.e., renal and cardiac failure), or were without adverse reactions.
Ti primeri so bili povezani z neželenimi učinki, ki so se ujemali z znanim varnostnim profilom lenvatiniba (t. j. odpoved ledvic in popuščanje srca), ali pa so bili brez neželenih učinkov.
The main efficacy outcome measure was progression-free survival (PFS) as determined by blinded independent radiologic review using Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.
Glavno merilo izida učinkovitosti je bilo preživetje brez napredovanja bolezni (progression-free survival ali PFS), ugotovljeno s slepim neodvisnim radiološkim pregledom z uporabo meril za ocenjevanje odziva pri čvrstih tumorjih (Response Evaluation Criteria in Solid Tumours ali RECIST) 1.1.
It is used on its own to treat progressive or advanced thyroid cancer in adults when radioactive iodine treatment has not helped to stop the disease.
Uporablja se za samostojno zdravljenje napredujočega ali napredovalega raka ščitnice pri odraslih, če zdravljenje z radioaktivnim jodom ni pomagalo zaustaviti bolezni.
Target lesions previously treated with radiotherapy or locoregional therapy had to show radiographic evidence of disease progression.
Za ciljne lezije, predhodno zdravljene z radioterapijo ali lokoregionalno terapijo, je bilo treba radiografsko potrditi napredovanje bolezni.
Consequently, in vivo, inducers and inhibitors of CYP 3A4 had a minimal effect on lenvatinib exposure (see section 4.5).
Zato so in vivo spodbujevalci in zaviralci CYP 3A4 imeli minimalen učinek na izpostavljenost lenvatinibu (glejte poglavje 4.5).
Noninferiority margin for hazard ratio (HR: lenvatinib vs sorafenib = 1.08).
Meja neinferiornosti za razmerje ogroženosti (HR: lenvatinib proti sorafenibu = 1,08).
Magnetic resonance imaging is necessary to confirm the diagnosis of PRES.
Za potrditev diagnoze PRES je potrebno slikanje z magnetno resonanco.
Kaplan-Meier Curve of Overall Survival - HCC
Slika 2 Kaplan-Meierjeva krivulja celotnega preživetja - HCC
Over this range, the median accumulation index (Rac) ranged from 0.96 (20 mg) to 1.54 (6.4 mg).
V tem območju je mediani indeks kopičenja (Rac) segal od 0,96 (20 mg) do 1,54 (6,4 mg).
• The capsules come in blisters of polyamide/aluminium/PVC with a push through aluminium foil lidding in cartons of 30,60 or 90 hard capsules.
• Kapsule so na voljo v pretisnih omotih iz poliamida/aluminija/PVC, prekritih z aluminijevo folijo za predrtje, v kartonskih škatlah s po 30, 60 ali 90 trdimi kapsulami.
For those patients already on antihypertensive medication, the dose of the current agent may be increased, if appropriate, or one or more agents of a different class of antihypertensive should be added.
Pri tistih bolnikih, ki že jemljejo antihipertenzivno zdravilo, je treba zvečati odmerek tega zdravila, če je to primerno, ali dodati eno ali več zdravil iz druge skupine antihipertenzivov.
You may need to have additional treatment with other medicines, to take a lower dose of LENVIMA, or to take extra care due to an increased risk of side effects.
Mogoče se boste morali dodatno zdraviti z drugimi zdravili, jemati manjši odmerek zdravila LENVIMA ali pa biti zaradi zvečanega tveganja neželenih učinkov še posebej pazljivi.
Antihypertensive agents should be started as soon as elevated BP is confirmed.
Antihipertenzivna zdravila je treba začeti dajati, takoj ko je zvišan KT potrjen.
Blood pressure (BP) should be well controlled prior to treatment with lenvatinib and, if patients are known to be hypertensive, they should be on a stable dose of antihypertensive therapy for at least 1 week prior to treatment with lenvatinib.
Krvni tlak (KT) naj bo pred zdravljenjem z lenvatinibom dobro nadzorovan in, če je za bolnike znano, da so hipertenzivni, naj bodo vsaj 1 teden pred zdravljenjem z lenvatinibom na stabilnem odmerku antihipertenzivne terapije.
A statistically significant prolongation in PFS was demonstrated in lenvatinib-treated patients compared with those receiving placebo (p<0.0001) (see figure 1).
Statistično značilno podaljšanje PFS so dokazali pri bolnikih, zdravljenih z lenvatinibom, v primerjavi s tistimi, ki so prejemali placebo (p < 0,0001) (glejte sliko 1).
When administered with food to healthy subjects, peak plasma concentrations are delayed by 2 hours.
Kadar ga dajemo zdravim preiskovancem z obrokom hrane, se najvišje plazemske koncentracije zakasnijo za 2 uri.
For the following transporters, OAT1, OAT3, OATP1B1, OCT1, OCT2, and BSEP, clinically relevant inhibition was excluded based on a cutoff of IC50> 50  Cmax,unbound.
Za prenašalce OAT1, OAT3, OATP1B1, OCT1, OCT2 in BSEP so klinično pomembno inhibicijo izključili na podlagi meje IC50 > 50  Cmax,nevezan.
Thyroid stimulating hormone (TSH) levels should be monitored on a regular basis and thyroid hormone administration should be adjusted to reach appropriate TSH levels, according to the patient's therapeutic target.
Raven tirotropnega hormona (thyroid stimulating hormone ali TSH) je treba redno spremljati in prilagoditi dajanje ščitničnega hormona tako, da bo TSH dosegel ustrezno raven v skladu z bolnikovim terapevtskim ciljem.
Your doctor can give you medicine to reduce these side effects.
Zdravnik vam bo lahko dal zdravilo, ki bo zmanjšalo te neželene učinke.
Second occurrence (same reaction or new reaction)
Drugi pojav (enak učinek ali nov učinek)
The primary efficacy endpoint was Overall Survival (OS).
Primarni opazovani dogodek je bilo celotno preživetje (OS - overall survival).
This binding was mainly to albumin with minor binding to α1-acid glycoprotein and γ-globulin.
Ta vezava je bila v glavnem na albumine z manjšo vezavo na α1-kisli glikoprotein in γ-globulin.
• changes in urine tests for protein (high) and urinary infections (increased frequency in urination and pain in passing urine)
• spremembe urinskih preiskav beljakovin (zvišane) in okužbe sečil (pogostnejše uriniranje in bolečine pri uriniranju),
Blood pressure should be well controlled prior to treatment with lenvatinib, and should be regularly monitored during treatment (see section 4.4).
Krvni tlak mora biti pred zdravljenjem z lenvatinibom dobro nadzorovan, med zdravljenjem pa ga je treba redno spremljati (glejte poglavje 4.4).
Not Known (the following side effects have been reported since the marketing of LENVIMA but the frequency for them to occur is not known)
Neznana pogostnost (o naslednjih neželenih učinkih so poročali, odkar je prišlo zdravilo LENVIMA na trg, vendar pogostnost, s katero se pojavljajo, ni znana):
The choice of antihypertensive treatment should be individualised to the patient's clinical circumstances and follow standard medical practice.
Izbiro antihipertenzivnega zdravljenja je treba pri vsakem bolniku prilagoditi njegovim kliničnim okoliščinam in ravnati v skladu s standardno medicinsko prakso.
In both treatment arms in the REFLECT study, median OS was approximately 9 months longer in subjects who received post-treatment anticancer therapy than in those who did not.
V obeh terapevtskih skupinah v študiji REFLECT je bilo mediano OS približno 9 mesecev daljše pri osebah, ki so po zdravljenju prejele onkološko terapijo, kot pri tistih, ki je niso.
In human liver cytosol, lenvatinib did not inhibit aldehyde oxidase activity.
V citosolu človeških jeter lenvatinib ni zaviral aktivnosti aldehidne oksidaze.
• have had recent surgery or radiotherapy
• ste pred nedavnim imeli operacijo ali zdravljenje z obsevanjem;
No specific studies with lenvatinib have been conducted in animals to evaluate the effect on fertility.
Z lenvatinibom niso opravili specifičnih študij na živalih za oceno učinka na plodnost.
Grades are based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
Stopnje temeljijo na Skupnih terminoloških merilih za neželene učinke (Common Terminology Criteria for Adverse Events oziroma CTCAE) Nacionalnega inštituta za raka (National Cancer Institute oziroma NCI).
Hypothyroidism should be treated according to standard medical practice to maintain euthyroid state.
Hipotiroidizem je treba zdraviti v skladu s standardno medicinsko prakso, da se vzdržuje evtiroidno stanje.
A clinical drug-drug interaction (DDI) study in cancer patients showed that plasma concentrations of midazolam (a sensitive CYP3A and Pgp substrate) were not altered in the presence of lenvatinib.
Klinična študija o medsebojnem delovanju zdravil (DDI - drug-drug interaction) pri bolnikih z rakom je pokazala, da se plazemske koncentracije midazolama (občutljivega substrata CYP3A in Pgp) v prisotnosti lenvatiniba ne spremenijo.
Before taking LENVIMA, your doctor may carry out some tests, for example to check your blood pressure and your liver or kidney function and to see if you have low levels of salt and high levels of thyroid stimulating hormone in your blood.
Pred začetkom jemanja zdravila LENVIMA vam lahko zdravnik naredi nekatere preiskave, lahko vam na primer kontrolira krvni tlak in delovanje jeter ali ledvic in se prepriča, ali imate nizko raven soli in visoko raven tirotropnega hormona v krvi.
Third occurrence (same reaction or new reaction)
Tretji pojav (enak učinek ali nov učinek)
• If you could become pregnant, use highly effective contraception while taking this medicine, and for at least one month after you finish treatment.
• Če je možno, da bi lahko zanosili, morate med jemanjem tega zdravila in vsaj še en mesec po končanem zdravljenju uporabljati učinkovito kontracepcijo.
Tell your doctor straight away if you notice any of the side effects above.
Nemudoma povejte zdravniku, če opazite kakega od zgoraj navedenih neželenih učinkov.
≥ 2 g / 24 hours
≥ 2 g/24 ur prekinite
Approximately half of the events of hepatic failure and one third of the events of the hepatic encephalopathy were reported in patients with disease progression.
Približno polovico dogodkov odpovedi jeter in eno tretjino dogodkov jetrne encefalopatije so zabeležili pri bolnikih z napredovanjem bolezni.
Includes all haemorrhage terms.
Vključuje vse izraze za krvavitev.
LENVIMA blocks the action of proteins called receptor tyrosine kinases (RTKs), which are involved in the development of new blood vessels that supply oxygen and nutrients to cells and help them to grow.
Zdravilo LENVIMA zavira delovanje beljakovin, ki se imenujejo receptorji tirozin-kinaze (RTK), ki so vpletene v razvoj novih krvnih žil, ki preskrbujejo celice s kisikom in hranilnimi snovmi in jim pomagajo rasti.
4.7 Effects on ability to drive and use machines Lenvatinib has a minor influence on the ability to drive and use machines, due to undesirable effects such as fatigue and dizziness.
Lenvatinib ima blag vpliv na sposobnost vožnje in upravljanja s stroji, in to zaradi neželenih učinkov, kot sta utrujenost in omotica.
In addition, lenvatinib had selective, direct antiproliferative activity in hepatocellular cell lines dependent on activated FGFR signalling, which is attributed to the inhibition of FGFR signalling by lenvatinib.
Poleg tega ima lenvatinib selektivno, neposredno antiproliferativno aktivnost v hepatocelularnih celičnih linijah, odvisno od aktivirane signalizacije FGFR, kar je posledica zaviranja signalizacije FGFR z lenvatinibom.
Plasma concentrations decline bi-exponentially following Cmax.
Koncentracije v plazmi se po Cmax zmanjšujejo bieksponencialno.
Of the 392 patients randomised, 76.3% were naïve to prior VEGF/VEGFR-targeted therapies, 49.0% were female, 49.7% were European, and the median age was 63 years.
Od 392 randomiziranih bolnikov jih 76,3 % nikoli prej ni prejemalo zdravljenja, usmerjenega v VEGF/VEGFR, 49,0 % jih je bilo ženskega spola, 49,7 % je bilo Evropejcev, mediana starost pa je bila 63 let.
For haematologic toxicity, dosing can restart when resolved to Grade 2; proteinuria, resume when resolves to less than 2g/24 hours e.
Pri hematološki toksičnosti se lahko odmerjanje ponovno začne, če se izboljša na stopnjo 2; pri proteinuriji odmerjanje nadaljujte, ko se izboljša na manj kot 2 g/24 ur.
In post-marketing surveillance, serious and fatal carotid artery haemorrhages were seen more frequently in patients with anaplastic thyroid carcinoma (ATC) than in DTC or other tumour types.
Pri nadzoru po prihodu zdravila na trg so ugotavljali resne in smrtne krvavitve karotidnih arterij pogosteje pri bolnikih z anaplastičnim tireoidnim karcinomom (ATC) kot pri DTC ali drugih vrstah tumorjev.
The majority of Grade 3 to 4 adverse reactions occurred during the first 6 months of treatment except for diarrhoea, which occurred throughout treatment, and weight loss, which tended to be cumulative over time.
Večina neželenih učinkov stopnje 3 do 4 se je pojavila v prvih 6 mesecih zdravljenja, razen driske, ki se je pojavljala ves čas zdravljenja, in hujšanja, ki je sčasoma postajalo čedalje izrazitejše.
Lenvatinib dose should be interrupted or dose adjusted as necessary depending on severity, presence of ECG changes, and persistence of hypocalcaemia.
Po potrebi je treba prekiniti odmerjanje lenvatiniba ali odmerek prilagoditi, odvisno od resnosti, prisotnosti sprememb EKG in trdovratnosti hipokalciemije.
Electrolyte disturbances such as hypokalaemia, hypocalcaemia, or hypomagnesaemia increase the risk of QT prolongation; therefore, electrolyte abnormalities should be monitored and corrected in all patients before starting treatment.
Motnje elektrolitov, na primer hipokaliemija, hipokalciemija ali hipomagneziemija, zvečujejo tveganje podaljšanja intervala QT, zato moramo spremljati in popraviti motnje elektrolitov pri vseh bolnikih, preden začnemo z zdravljenjem.
The SELECT study was a multicentre, randomised, double-blind, placebo-controlled trial that was conducted in 392 patients with radioiodine-refractory differentiated thyroid cancer with independent, centrally reviewed, radiographic evidence of disease progression within 12 months (+1 month window) prior to enrolment.
Študija SELECT je bila multicentrično, randomizirano, dvojno slepo, s placebom kontrolirano preskušanje, opravljeno pri 392 bolnikih z diferenciranim rakom ščitnice, odpornim proti radioaktivnemu jodu, z neodvisno ugotovljenimi, centralno pregledovanimi radiografskimi znaki napredovanja bolezni v 12 mesecih (+ 1-mesečno okno) pred vključitvijo.
Eligible patients with measurable disease according to RECIST 1.1 were randomised 2:1 to receive lenvatinib 24 mg once daily (n=261) or placebo (n=131).
Primerni bolniki z merljivo boleznijo po RECIST 1.1 so bili randomizirani v razmerju 2:1 na prejemanje lenvatiniba 24 mg enkrat na dan (n=261) ali placeba (n=131).
• bleeding (most commonly nose bleeds, but also other types of bleeding such as blood in the urine, bruising, bleeding from the gums or gut wall)
• krvavitve (najpogosteje krvavitve iz nosu, lahko pa tudi druge vrste krvavitev, na primer kri v urinu, modrice, krvavitve iz dlesni ali črevesne stene),
Hepatic encephalopathy also occurred more frequently in patients aged 75 years and older.
Jetrna encefalopatija se je pogosteje pojavila pri bolnikih, starih 75 let ali več.
In vitro binding of lenvatinib to human plasma proteins is high and ranged from 98% to 99% (0.3 - 30 μg/mL, mesylate).
Vezava lenvatiniba na beljakovine humane plazme in vitro je velika, v razponu od 98 % do 99 % (0,3-30 μg/ml, mesilat).
Lenvatinib exhibited good oral bioavailability in dogs (70.4%) and monkeys (78.4%).
Lenvatinib je pokazal dobro peroralno biološko uporabnost pri psih (70,4 %) in opicah
• severe pain in your belly (abdomen) - this may be due to a hole in the wall of your gut or a fistula (a hole in your gut which links through a tube-like passage to another part of your body or skin).
• močna bolečina v trebuhu (abdomnu) - ta lahko nastane zaradi luknje v steni črevesa ali fistule (luknja v črevesu, ki je po cevastem prehodu povezana z drugim delom vašega telesa ali kožo);
Dose adjustments and Discontinuation for HCC
Prilagajanje odmerka in ukinitev pri HCC
Appropriate measures should be taken to control blood pressure (see section 4.4, Hypertension).
Uvesti je treba primerne ukrepe za obvladanje krvnega tlaka (glejte poglavje 4.4 Hipertenzija).
The primary risk factor identified was dehydration and/or hypovolemia due to gastrointestinal toxicity.
Ugotovili so, da je bil primarni dejavnik tveganja dehidracija in/ali hipovolemija zaradi toksičnosti za prebavila.
The hepatic failure cases were generally reported in patients with progressive metastatic liver metastases disease.
O primerih odpovedi jeter so na splošno poročali pri bolnikih s progresivno metastatsko jetrno boleznijo.
Polyamide/Aluminium/PVC/Aluminium blisters containing 10 capsules.
Pretisni omoti iz poliamida/aluminija/PVC/aluminija, ki vsebujejo po 10 kapsul.
Adverse reactions observed in clinical trials in DTC and HCC and reported from post-marketing use of lenvatinib are listed in Table 5.
Neželeni učinki, ki so jih ugotovili v kliničnih preskušanjih pri DTC in HCC ter o katerih so poročali pri uporabi lenvatiniba v obdobju trženja, so navedeni v preglednici 5.
Haematologic toxicity or proteinuria-no dose adjustment required for first occurrence.
Hematološka toksičnost ali proteinurija: pri prvem pojavu prilagajanje odmerka ni potrebno.
Manufacturer Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom.
Proizvajalec Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, Velika Britanija.
• Caregivers should not open the capsules to avoid exposure to the contents of the capsule.
• Skrbniki bolnikov naj ne odpirajo kapsul, da ne bodo prišli v stik z vsebino kapsule.
Patients with end-stage renal disease were not studied, therefore the use of lenvatinib in these patients is not recommended.
Bolnikov z boleznijo ledvic v končnem stadiju niso proučevali, zato uporaba lenvatiniba pri teh bolnikih ni priporočljiva.
The positive effect on PFS was seen across the subgroups of age (above or below 65 years), sex, race, histological subtype, geographic region, and those who received 0 or 1 prior VEGF/VEGFR-targeted therapies.
Pozitivni učinek na PFS je bil viden v podskupinah po starosti (več ali manj kot 65 let), spolu, rasi, histološki podvrsti, zemljepisni regiji in tistih, ki so prejeli 0 ali 1 predhodna zdravljenja, usmerjena v VEGF/VEGFR.
Mild to severe hypertension may be present.
Lahko je prisotna blaga do huda hipertenzija.
Reduce dose in succession based on the previous dose level (12 mg, 8 mg, 4 mg or 4 mg every other day).
Odmerek zmanjšajte v korakih glede na predhodni odmerek (12 mg, 8 mg, 4 mg ali 4 mg vsak drugi dan).
Symptoms and Management
Simptomi in zdravljenje
The overall survival analysis was confounded by the fact that placebo-treated subjects with confirmed disease progression had the option to cross over to open-label lenvatinib.
Analizo celotnega preživetja je otežilo dejstvo, da so preiskovanci s potrjenim napredovanjem bolezni, ki so prejemali placebo, imeli možnost izbire prehoda na odprti lenvatinib.
In vitro transporter studies
Študije prenašalcev in vitro
LENVIMA can also be used on its own to treat liver cancer (hepatocellular carcinoma) in adults who have not previously been treated with another anticancer medicine that travels through the bloodstream.
Zdravilo LENVIMA se lahko uporablja tudi za samostojno zdravljenje raka jeter (hepatocelularnega karcinoma) pri odraslih, ki še niso bili zdravljeni z drugim zdravilom proti raku, ki potuje po krvnem obtoku.
A risk to newborns or infants cannot be excluded and, therefore, lenvatinib is contraindicated during breast-feeding (see section 4.3).
Tveganja za novorojenčke ali dojenčke ni mogoče izključiti, zato je lenvatinib med dojenjem kontraindiciran (glejte poglavje 4.3).
In 1.1% of patients, hypertension led to permanent treatment discontinuation.
Pri 1,1 % bolnikov je hipertenzija povzročila trajno ukinitev zdravljenja.
P-value is for the superiority test of lenvatinib versus sorafenib.
d Vrednost p velja za preskus superiornosti lenvatiniba v primerjavi s sorafenibom.
Lenvatinib is a multikinase inhibitor which has shown mainly antiangiogenic properties in vitro and in vivo, and direct inhibition of tumour growth was also observed in in vitro models.
Lenvatinib je multikinazni inhibitor, ki je in vitro in in vivo pokazal predvsem antiangiogene lastnosti, v modelih in vitro pa so opazili tudi neposredno inhibicijo rasti tumorjev.
• Absence of MPVI, extra-hepatic tumour spread (EHS) or both: 30%
• odsotnost MPVI, razširjenost tumorja izven jeter (EHS - extra-hepatic tumour spread) ali oboje:
Hepatic encephalopathy occurred at more than twice the incidence in patients aged ≥75 years (17.2%) than in those <75 years (7.1%).
Jetrna encefalopatija se je pojavila več kot dvakrat pogosteje pri bolnikih, starih ≥ 75 let (17,2 %), kot pri bolnikih, starih < 75 let (7,1 %).
Lenvatinib should be discontinued in the event of persistence of Grade 4 diarrhoea despite medical management.
Lenvatinib je treba ukiniti v primeru driske stopnje 4, ki vztraja kljub medicinski obravnavi.
• anal fistula (a small channel that forms between the anus and the surrounding skin)
• analna fistula (majhen kanal, ki nastane med zadnjikom in okolno kožo),
There have also been reports of overdose with lenvatinib involving single administrations of 6 to 10 times the recommended daily dose.
Poročali so tudi o prevelikem odmerjanju lenvatiniba, kjer so bili enkratni odmerki 6-krat do 10-krat večji od priporočenega dnevnega odmerka.
Lenvatinib showed minimal or no inhibitory effect on OATP1B3 and MATE2-K. Lenvatinib weakly inhibits MATE1.
Lenvatinib je pokazal minimalen ali nikakršen inhibicijski učinek na OATP1B3 in MATE2-K. Lenvatinib šibko inhibira MATE1.
Close monitoring of overall safety is recommended in these patients (see sections 4.4 and 5.2).
Pri teh bolnikih je priporočljivo natančno spremljanje celotne varnosti (glejte poglavji 4.4 in 5.2).
Lenvatinib should be withheld in the event of development of QT interval prolongation greater than 500 ms. Lenvatinib should be resumed at a reduced dose when QTc prolongation is resolved to < 480 ms or baseline.
Dajanje lenvatiniba je treba prekiniti, če se razvije podaljšanje intervala QT, ki presega 500 ms. Lenvatinib je treba spet začeti dajati v zmanjšanem odmerku, ko se podaljšanje intervala QTc vrne na < 480 ms ali izhodiščno vrednost.
Electrolytes (magnesium, potassium and calcium) should be monitored periodically during treatment.
Med zdravljenjem je treba v rednih časovnih presledkih spremljati elektrolite (magnezij, kalij in kalcij).
Blood calcium levels should be monitored at least monthly and calcium should be replaced as necessary during lenvatinib treatment.
Raven kalcija v krvi je treba spremljati vsaj enkrat na mesec in med zdravljenjem z lenvatinibom kalcij po potrebi nadomeščati.
LENVIMA treatment should be initiated and supervised by a health care professional experienced in the use of anticancer therapies.
Zdravljenje z zdravilom LENVIMA mora uvesti in nadzorovati zdravnik z izkušnjami pri uporabi zdravil proti raku.
• other types of fistulae (an abnormal connection between different organs in the body or between the skin and an underlying structure such as throat and windpipe).
• druge vrste fistul (fistula je nenormalna povezava med različnimi telesnimi organi ali med kožo in spodaj ležečo strukturo, na primer žrelom in sapnikom).
• If you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.
• imate ali ste imeli anevrizmo (razširitev in oslabitev stene krvne žile) ali raztrganino v steni krvne žile.
Prompt medical management of diarrhoea should be instituted in order to prevent dehydration.
Začeti moramo takojšnjo medicinsko obravnavo driske, da preprečimo dehidracijo.
Systolic BP ≥140 mmHg up to <160 mmHg or diastolic BP ≥90 mmHg up to <100 mmHg
Priporočeno ukrepanje sistolični KT ≥ 140 mmHg do < 160 mmHg ali diastolični KT ≥ 90 mmHg do < 100 mmHg
Systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg despite optimal antihypertensive therapy
sistolični KT ≥ 160 mmHg ali diastolični KT ≥ 100 mmHg kljub optimalni antihipertenzivni terapiji